INTRAVENOUS OR ORAL I-131 TREATMENT OF THYROTOXICOSIS AND THYROID-CANCER

被引：0

作者：

MULLER, KD ^{[1
]}

GREBE, SF ^{[1
]}

BOCK, FL ^{[1
]}

MULLER, H ^{[1
]}

FANGEWISCH, GL ^{[1
]}

机构：

[1] UNIV GIESSEN,NUKL MED ABT,W-6300 GIESSEN,GERMANY

来源：

NUKLEARMEDIZIN | 1994年 / 33卷 / 03期

关键词：

THYROID; RADIOIODINE THERAPY; I-131; DOSE CALCULATION; BIOKINETICS;

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The purpose of this study was to determine differences in I-131 biokinetics after oral or intravenous treatment of hyperthyroidism (0,81 GBq) or differentiated thyroid cancer (1,85 GBq) following thyroidectomy. 20 patients with differentiated carcinoma and 20 patients with hyperthyroidism were studied. In each group 10 patients were treated perorally and 10 patients intravenously. The integrated whole-body activities during therapy were significantly lower, by an average 23% (cancer) and 45% (hyperthyroidism) than after oral application. It is most likely that these differences between oral and intravenous application are due to the higher serum activity after intravenous therapy. It is concluded that a higher activity dose of I-131 must be given orally to achieve the same target dose as after intravenous application.

引用

页码：87 / 92

页数：6

共 50 条

[41] Received dose variability after administration of I-131 for treatment of hyperthyroidism in cats
Busser, Suzanne
Poirier, Valerie J.
Liggins, Carolyn
Bray, Sharyn
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2021, 35 (04) : 1697 - 1702
[42] I-131, I-123, and F-18 FDG-PET Imaging in a Patient With Diffuse Sclerosing Variant of Papillary Thyroid Cancer
Wong, Terence Z.
Jain, Manoj K.
Spratt, Susan E.
CLINICAL NUCLEAR MEDICINE, 2008, 33 (12) : 834 - 837
[43] Advances in Antioxidant Applications for Combating 131I Side Effects in Thyroid Cancer Treatment
Yang, Li
Ma, Jiahui
Lei, Pengyu
Yi, Jia
Ma, Yilei
Huang, Zhongke
Wang, Tingjue
Ping, Haiyan
Ruan, Danping
Sun, Da
Pan, Hongying
TOXICS, 2023, 11 (06)
[44] Hospital discharge policy in thyroid cancer patients treated with I-131: The effect of changing from fixed time to exposure rate threshold
Mohammadi, H
Saghari, M
HEALTH PHYSICS, 1997, 72 (03): : 476 - 480
[45] The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation
Watanabe, Ken
Uchiyama, Mayuki
Fukuda, Kunihiko
JAPANESE JOURNAL OF RADIOLOGY, 2017, 35 (09) : 505 - 510
[46] A Comparison Between Diagnostic I-123 and Posttherapy I-131 Scans in the Detection of Remnant and Locoregional Thyroid Disease
Thomas, Damita L.
Menda, Yusuf
Bushnell, David
CLINICAL NUCLEAR MEDICINE, 2009, 34 (11) : 745 - 748
[47] The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation
Ken Watanabe
Mayuki Uchiyama
Kunihiko Fukuda
Japanese Journal of Radiology, 2017, 35 : 505 - 510
[48] THERAPEUTIC EFFICIENCY OF AUTONOMOUS NODULE OF THE THYROID AND TOXIC MULTINODULAR GOITER WITH I-131 - ABOUT 59 CASES
GUERMAZI, F
FEKIH, MAA
KRAIEM, A
MTIMET, S
ANNALES D ENDOCRINOLOGIE, 1991, 52 (05) : 323 - 326
[49] Influence of measurement geometry on the estimate of I-131 activity in the thyroid: Monte Carlo simulation of a detector and a phantom
Ulanovsky, AV
Minenko, VF
Korneev, SV
HEALTH PHYSICS, 1997, 72 (01): : 34 - 41
[50] POTASSIUM IODATE AND ITS COMPARISON TO POTASSIUM-IODIDE AS A BLOCKER OF I-131 UPTAKE BY THE THYROID IN RATS
PAHUJA, DN
RAJAN, MGR
BORKAR, AV
SAMUEL, AM
HEALTH PHYSICS, 1993, 65 (05): : 545 - 549

← 1 2 3 4 5 →